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Early Diagnosis of 
Disseminated 
Mycobacterium 
genavense Infection 
To the Editor: Nontuberculous 
mycobacteria are environmental or-
ganisms that cause life-threatening 
diseases, particularly in immunocom-
promised hosts. They are increasingly 
recognized for causing problems in 
the management of solid-organ trans-
plant recipients, due to improved di-
agnostic methods as well as increasing 
numbers and life expectancy of these 
patients (1). The slow-growing Myco-
bacterium genavense is a ubiquitous 
nontuberculous mycobacterium; it is 
reportedly isolated from tap water, 
pets, and the gastrointestinal tract of 
healthy humans (1,2). It was ﬁ  rst rec-
ognized as a human pathogen in a pa-
tient with AIDS but has not yet been 
found in heart transplant recipients 
(3). We report early diagnosis of dis-
seminated M. genavense infection in a 
heart transplant recipient.
A 37-year-old man was hospital-
ized in September 2001 for abdomi-
nal pain, sweats, and weight loss; he 
had received a heart transplant 3 years 
earlier. Immunosuppressive treatment, 
which began immediately after trans-
plantation, consisted of tacrolimus (5 
mg) and mycophenolate mofetil (2 g) 
daily; concurrent steroid therapy was 
tapered off over the next 6 months. 
A computed tomographic (CT) scan 
showed numerous large lymph nodes 
in his abdomen (Figure). Endoscopic 
examinations showed diffuse inﬂ  am-
mation of the mucosa of the duodenum, 
ileum, and colon. Multiple biopsy 
samples were submitted for histologic 
analysis, culture, and molecular bio-
logical analysis. Immediate 16S rRNA 
gene ampliﬁ  cation that used universal 
primers (4) and sequencing of sam-
ples taken directly from the biopsy 
material led to the identiﬁ  cation of M. 
genavense. A 475-bp fragment was 
sequenced, and 99% homology with 
the gene of type strain ATCC 51234 
(GenBank accession no. X60070) was 
found. PCR results were positive for 2 
of the 4 samples tested. The molecular 
identiﬁ  cation was compatible with the 
subsequent histologic ﬁ  nding of pro-
found macrophage inﬁ  ltration  with-
out granuloma and the presence of 
Ziehl-Neelsen–positive bacilli. Five 
weeks later, the molecular diagno-
sis was conﬁ  rmed by blood cultures 
and cultures of the intestinal mucosa 
samples (Inno-LiPA Mycobacteria 
test, version 2, Innogenetics, Courta-
boeuf, France). The direct molecular 
diagnosis of M. genavense enabled 
immediate treatment of the patient 
with the combination of moxiﬂ  oxa-
cin, ethambutol, clarithromycin, and 
amikacin; mycophenolate mofetil was 
discontinued. Clofazimine was added 
to the treatment regimen 3 months 
later, when a control CT scan showed 
that some of the enlarged mesenteric 
lymph nodes had increased further. 
After 5 months, the clinical signs re-
solved, and after 9 months, the lymph 
nodes were substantially smaller. CT 
scan results were within normal lim-
its after 12 months of treatment; only 
ethambutol and clarithromycin were 
continued for an additional 6 months. 
There was no sign of M. genavense 
infection relapse 3 years after the di-
agnosis had been made. 
Nontuberculous mycobacteria in 
persons who have received heart or 
other solid-organ transplants remain 
a rare cause of late infectious com-
plications and occur ≈3.5 years after 
transplantation (1,4). In the subgroup 
of heart transplant recipients, skin dis-
ease is the most common clinical man-
ifestation, followed by pulmonary and 
disseminated disease; M. kansasii, M. 
avium complex, and M. haemophilum 
infections are most frequently encoun-
tered (1,5).
M. genavense causes up to 12.8% 
of all nontuberculous mycobacteria 
infections in AIDS patients; these in-
fections are clinically similar to those 
caused by the M. avium complex (1,6). 
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Figure. Initial computed tomographic scan of the abdomen, performed after intravenous 
injection of contrast dye, showing numerous enlarged para-aortic lymph nodes (arrow).LETTERS
M. genavense infections occur only 
rarely in persons other than AIDS 
patients (as in the present case), but 
they always occur in immunocom-
promised persons (7,8). To date, only 
1 case of disseminated infection has 
been reported in a solid-organ (kid-
ney) transplant recipient; the diag-
nosis was made by molecular iden-
tiﬁ  cation in isolates from blood and 
marrow cultures. That patient died of 
complications from M. genavense in-
fection (9). Because M. genavense is 
a fastidious organism, the infections 
it causes are difﬁ  cult to diagnose and 
their frequency is probably underes-
timated, which may change with in-
creased use of direct molecular bio-
logical methods.
Optimal treatment of M. ge-
navense infections has not been es-
tablished (10). Experience with M. 
genavense infections in AIDS patients 
and with other nontuberculous myco-
bacteria infections in solid-organ trans-
plant recipients suggests that at least 
2 antimicrobial drugs should be used 
for a prolonged period; when possible, 
immunosuppressive drugs should be 
concurrently reduced (1,3,6,10). Out-
come of nontuberculous mycobacte-
ria infections in transplant patients is 
highly variable (1,5) but was satisfac-
tory in the present patient, who was 
treated with quintuple antimicrobial-
drug therapy and reduced immuno-
suppressive therapy.
This case of a disseminated infec-
tion due to M. genavense in a heart 
transplant recipient was diagnosed 
early. Universal 16S rRNA gene se-
quencing after ampliﬁ  cation  directly 
from intestinal biopsy specimens en-
abled fast diagnosis and appropriate 
management.
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Isolation of Novel 
Adenovirus from 
Fruit Bat (Pteropus 
dasymallus 
yayeyamae)
To the Editor: Bats are thought to 
be one of the most important reservoirs 
for viruses such as Nipah virus, severe 
acute respiratory syndrome (SARS) 
coronavirus, and Ebola virus (1). 
These pathogens became known after 
extensive surveys of bats following 
outbreaks. As a ﬁ  rst step in investigat-
ing unidentiﬁ  ed pathogens in bats and 
to help forecast the potential threat of 
emerging infectious diseases, we tried 
to isolate and characterize viruses that 
persistently infect bats. In the process, 
we isolated a novel adenovirus from a 
fruit bat in Japan. 
Pteropus dasymallus yayeyamae, 
or Ryukyu ﬂ  ying fox, is a fruit bat of 
Japan. With the permission of the gov-
ernor of Okinawa, we caught 1 adult 
male bat of this species and used its 
spleen and kidneys to establish pri-
mary cell cultures. On the 4th passage 
of the primary adherent cells derived 
from the spleen, a cytopathic effect 
(CPE) appeared without any visible 
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